Chemomab Therapeutics to Present at Aegis Virtual Conference

Rhea-AI Summary

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotechnology company, announced it will present at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET. The company focuses on innovative therapeutics for fibrotic and inflammatory diseases, highlighting its monoclonal antibody CM-101, designed to block the soluble protein CCL24, which is linked to these conditions. CM-101 is currently undergoing two Phase 2 trials for primary sclerosing cholangitis and liver fibrosis, with a third trial in systemic sclerosis anticipated to start in early 2022.

TEL AVIV, Israel, Feb. 10, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 24, 2022, at 9:00 am ET.

To access the event: click https://us02web.zoom.us/j/86168915443

A copy of Chemomab's presentation will also be available on Chemomab's website at https://investors.chemomab.com/ starting on February 24, 2022.

For additional information on accessing the Chemomab presentation, click on Aegis Virtual Conference Calendar.

About Chemomab Therapeutics Ltd.

Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 safety and efficacy trials—one in patients with primary sclerosing cholangitis and the second in patients with liver fibrosis, with a third Phase 2 trial in systemic sclerosis expected to begin early in 2022. For more information on Chemomab, visit chemomab.com.

Contacts:

Investor Relations: 
Irina Koffler                                                      
LifeSci Advisors, LLC                                       
Phone: +1-917-734-7387                                   
ir@chemomab.com                                  

Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations, Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com 

View original content:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-present-at-aegis-virtual-conference-301479592.html

SOURCE Chemomab Therapeutics Ltd

FAQ

What is Chemomab Therapeutics' presentation date at the Aegis Capital Corp. Virtual Conference?

Chemomab Therapeutics will present on February 24, 2022.

What is the focus of Chemomab Therapeutics?

Chemomab Therapeutics focuses on developing therapeutics for fibrotic and inflammatory diseases.

Where can I access the Chemomab presentation?

The presentation will be available on Chemomab's website and can also be accessed via the Aegis Capital Corp. Virtual Conference link.

What is CM-101 and its significance?

CM-101 is a monoclonal antibody developed by Chemomab to block CCL24, targeting severe fibrotic and inflammatory diseases.

What trials is Chemomab currently conducting for CM-101?

Chemomab is conducting two Phase 2 trials for CM-101, one for primary sclerosing cholangitis and another for liver fibrosis, with a third trial in systemic sclerosis expected in early 2022.